Nivolumab Fails as Single-agent Treatment for Advanced Uterine Leiomyosarcoma

Share this content:
Although nivolumab did not induce a response in any patients, the presence of tumor-associated macrophages may be a promising treatment avenue for novel combinations.
Although nivolumab did not induce a response in any patients, the presence of tumor-associated macrophages may be a promising treatment avenue for novel combinations.

Nivolumab is not an effective single-agent treatment for patients with advanced uterine leiomyosarcoma that progresses after at least 1 prior line of therapy, according to a study published in Cancer.1

Uterine sarcoma, which make up about 3% of uterine cancers, often display infiltration of tumor-associated macrophages, which may explain suppression of T cell function. For this phase 2 trial, researchers evaluated whether nivolumab, an immune checkpoint inhibitor, would effectively treat patients with uterine leiomyosarcoma who progressed after at least 1 prior therapy line.

Of 12 enrolled patients, 4 had 1 prior treatment line, 2 had 2 prior treatment lines, and 6 had at least 3 prior treatment lines. All patients were previously treated with a gemcitabine-based regimen.

All patients received nivolumab 3 mg/kg intravenously on day 1 of 2-week cycles. Nine patients discontinued treatment for disease progression, 1 patient had unconfirmed progression, and 2 patients discontinued at investigator's/patient's decision.

The objective response rate was 0%.

RELATED: Phase 2 Trial of Ablation Techniques in Metastatic Sarcoma

Grade 3 or worse toxicities “definitely” related to treatment included increased serum amylase and increased lipase.

The authors concluded that although nivolumab did not induce a response in any of these patients, the presence of tumor-associated macrophages in this setting may be a promising treatment avenue for novel combinations.

Reference

  1. Ben-Ami E, Barysauskas CM, Solomon S, et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer. 2017 Apr 26. doi: 10.1002/cncr.30738 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters